|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-12-23
|
|
pubmed:abstractText |
The T cell-mediated immune response elicited by Pneumocystis plays a key role in pulmonary damage and dysfunction during Pneumocystis carinii pneumonia (PcP). Mice depleted of CD4(+) and CD8(+) T cells prior to infection are markedly protected from PcP-related respiratory deficit and death, despite progressive lung infection. However, the therapeutic effectiveness of Ab-mediated disruption of T cell function in mice already displaying clinical symptoms of disease has not been determined. Therefore, a murine model of PcP-related immune reconstitution inflammatory syndrome was used to assess whether Ab to the pan-T cell molecule CD3 is effective for reducing the severity of PcP when administered after the onset of disease. Mice that received anti-CD3 Ab exhibited a rapid and dramatic halt in the PcP-associated pulmonary function decline within 1 week after treatment, and a striking enhancement of survival rate compared with mice receiving the control Ab. Physiologic improvement in anti-CD3 treated mice was associated with a significant reduction in the number of CD4(+) and CD8(+) T cells recovered in lung lavage fluid. This effectiveness of anti-CD3 was noted whether the mice also received antibiotic therapy with trimethoprim-sulfamethoxazole. These data suggest that monoclonal Ab-mediated disruption of T cell function may represent a specific and effective adjunctive therapy to rapidly reverse the ongoing pathologic immune response occurring during active PcP. Thus, the anti-human CD3 monoclonal Ab OKT3, which is already in clinical use, has the potential to be developed as an adjunctive therapy for PcP.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-10377126,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-10545529,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-10721706,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-11159965,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-11309715,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-12563296,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-13508884,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-1353767,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-14764724,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-15385471,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-15793106,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-15845480,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-16339567,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-16436661,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-16891394,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-16940142,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-18190281,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-1833451,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-18365995,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-18554841,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-2117637,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-2139668,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-2817582,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-2950524,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-6494618,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19949093-7697231
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1550-6606
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
184
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
497-502
|
|
pubmed:dateRevised |
2011-7-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19949093-Animals,
pubmed-meshheading:19949093-Anti-Infective Agents,
pubmed-meshheading:19949093-Antibodies,
pubmed-meshheading:19949093-Antigens, CD3,
pubmed-meshheading:19949093-Bronchoalveolar Lavage Fluid,
pubmed-meshheading:19949093-Disease Models, Animal,
pubmed-meshheading:19949093-Inflammation,
pubmed-meshheading:19949093-Lymphocyte Depletion,
pubmed-meshheading:19949093-Mice,
pubmed-meshheading:19949093-Pneumonia, Pneumocystis,
pubmed-meshheading:19949093-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:19949093-Trimethoprim-Sulfamethoxazole Combination
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Anti-CD3 antibody decreases inflammation and improves outcome in a murine model of Pneumocystis pneumonia.
|
|
pubmed:affiliation |
Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|
